International Journal of Molecular Sciences · 2023 · 11 citations · 31 references
Life SciencesImmunologyMicrobiologyHost-pathogen InteractionsInnate ImmunityMucosal ImmunologyImmune Responses To InfectionInnate Immune ModulationInnate Immune ResponseInnate Immune Signaling PathwaysMucosal Immune SystemToll-like ReceptorsImmune Response To Bacterial InfectionInnate Cytokine ResponsesMucosal Immunity To BacteriaMucosal Pattern Recognition ReceptorsRespiratory Tract ImmunityToll-like Receptor SignalingToll-like Receptor Signaling PathwaysToll-like Receptor-mediated Innate Immune Response
Previously, we isolated potentially probiotic Ligilactobacillus salivarius strains from the intestines of wakame-fed pigs. The strains were characterized based on their ability to modulate the innate immune responses triggered by the activation of Toll-like receptor (TLR)-3 or TLR4 signaling pathways in intestinal mucosa. In this work, we aimed to evaluate whether nasally administered L. salivarius strains are capable of modulating the innate immune response in the respiratory tract and conferring long-term protection against the respiratory pathogen Streptococcus pneumoniae. Infant mice (3-weeks-old) were nasally primed with L. salivarius strains and then stimulated with the TLR3 agonist poly(I:C). Five or thirty days after the last poly(I:C) administration mice were infected with pneumococci. Among the strains evaluated, L. salivarius FFIG58 had a remarkable ability to enhance the protection against the secondary pneumococcal infection by modulating the respiratory immune response. L. salivarius FFIG58 improved the ability of alveolar macrophages to produce interleukin (IL)-6, interferon (IFN)-γ, IFN-β, tumor necrosis factor (TNF)-α, IL-27, chemokine C-C motif ligand 2 (CCL2), chemokine C-X-C motif ligand 2 (CXCL2), and CXCL10 in response to pneumococcal challenge. Furthermore, results showed that the nasal priming of infant mice with the FFIG58 strain protected the animals against secondary infection until 30 days after stimulation with poly(I:C), raising the possibility of using nasally administered immunobiotics to stimulate trained immunity in the respiratory tract.
31
Christopher Troeger, Brigette F. Blacker, Puja C Rao et al. · The Lancet Infectious Diseases · 2018 · 2K citations · Full text
Yohsuke Tomosada, Eriko Chiba, Hortensia Zelaya et al. · BMC Immunology · 2013 · 165 citations · Full text
Julio Villena, Eriko Chiba, Yohsuke Tomosada et al. · BMC Immunology · 2012 · 146 citations · Full text
Keer Sun, Sharon L. Salmon, Steven A. Lotz et al. · Infection and Immunity · 2007 · 139 citations · Full text